IMDX

Company Overview — What Does Oncocyte Corp Do?

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Oncocyte Corp (IMDX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Joshua Riggs and employs approximately 120 people, headquartered in Alameda, California. With a market capitalization of $111M, IMDX is one of the notable companies in the Healthcare sector.

Oncocyte Corp (IMDX) Stock Rating — Avoid (April 2026)

As of April 2026, Oncocyte Corp receives a Avoid rating with a composite score of 31.2/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.IMDX ranks #4,031 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Oncocyte Corp ranks #702 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IMDX Stock Price and 52-Week Range

Oncocyte Corp (IMDX) currently trades at $3.12. The stock lost $0.06 (1.9%) in the most recent trading session. The 52-week high for IMDX is $8.51, which means the stock is currently trading -63.3% from its annual peak. The 52-week low is $2.33, putting the stock 33.9% above its annual trough. Recent trading volume was 415K shares, suggesting relatively thin trading activity.

Is IMDX Overvalued or Undervalued? — Valuation Analysis

Oncocyte Corp (IMDX) carries a value factor score of 14/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 34.07x, compared to 1.66x for the average Healthcare stock.

At current multiples, Oncocyte Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Oncocyte Corp Profitability — ROE, Margins, and Quality Score

Oncocyte Corp (IMDX) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -23603.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -158.3% versus the sector average of -33.1%.

On a margin basis, Oncocyte Corp reports gross margins of 56.6%, compared to 71.5% for the sector. The operating margin is -4554.9% (sector: -66.1%). Net profit margin stands at -4525.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 150.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IMDX Debt, Balance Sheet, and Financial Health

Oncocyte Corp has a debt-to-equity ratio of -28.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.27x, suggesting adequate working capital coverage. Total debt on the balance sheet is $3M. Cash and equivalents stand at $19M.

IMDX has a beta of 0.86, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Oncocyte Corp is 28/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Oncocyte Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, Oncocyte Corp reported revenue of $3M and earnings per share (EPS) of $-1.65. Net income for the quarter was $-41M. Gross margin was 56.6%. Operating income came in at $-41M.

In FY 2025, Oncocyte Corp reported revenue of $4M and earnings per share (EPS) of $-1.65. Net income for the quarter was $-50M. Gross margin was 56.7%. Revenue grew 115.6% year-over-year compared to FY 2024. Operating income came in at $-51M.

In Q3 2025, Oncocyte Corp reported revenue of $260,000 and earnings per share (EPS) of $-0.34. Net income for the quarter was $-11M. Gross margin was 53.5%. Revenue grew 126.1% year-over-year compared to Q3 2024. Operating income came in at $-11M.

In Q2 2025, Oncocyte Corp reported revenue of $518,000 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-10M. Gross margin was 67.6%. Revenue grew 398.1% year-over-year compared to Q2 2024. Operating income came in at $-10M.

Over the past 8 quarters, Oncocyte Corp has demonstrated a growth trajectory, with revenue expanding from $104,000 to $3M. Investors analyzing IMDX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IMDX Dividend Yield and Income Analysis

Oncocyte Corp (IMDX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IMDX Momentum and Technical Analysis Profile

Oncocyte Corp (IMDX) has a momentum factor score of 54/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.

IMDX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Oncocyte Corp (IMDX) ranks #702 out of 838 stocks based on the Blank Capital composite score. This places IMDX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IMDX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IMDX vs S&P 500 (SPY) comparison to assess how Oncocyte Corp stacks up against the broader market across all factor dimensions.

IMDX Next Earnings Date

No upcoming earnings date has been announced for Oncocyte Corp (IMDX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IMDX? — Investment Thesis Summary

The quantitative profile for Oncocyte Corp suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 14/100 indicates premium valuation. High volatility (stability score 28/100) increases portfolio risk.

In summary, Oncocyte Corp (IMDX) earns a Avoid rating with a composite score of 31.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IMDX stock.

Related Resources for IMDX Investors

Explore more research and tools: IMDX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IMDX head-to-head with peers: IMDX vs AZN, IMDX vs SLGL, IMDX vs VMD.